Cosciens Biopharma Inc. · TSX:CSCI

Cosciens Biopharma — Investor Presentation (September 2026)

14 slides from Cosciens Biopharma's investor presentation, September 2026

1. Slide 1: Leaders in Oral Thin Films

   LEADERS IN ORAL THIN FILMS Oral thin film drug delivery. Corporate Presentation – September 2026 Montréal, Québec, Canada VersaFilm® · VetaFilm® Non-Confidential

2. Slide 2: Disclaimer

   Disclaimer Cautionary Note This presentation has been prepared by the management of COSCIENS Biopharma Inc. (“Cosciens” or the “Company”) and its wholly-owned subsidiary, Nualtis Corp. (“Nualtis”) for informational purposes based on the Company’s public disclosure and other publicly available inform

3. Slide 3: 3

   3

4. Slide 4: Established industry leader and innovator of OTF drug delivery technology

   Established industry leader and innovator of OTF drug delivery technology VISION We leverage science and innovation to improve quality of life. 20+ years 30+ 34,500 sq. ft. Pioneering oral- U.S. patents Regulator- film science and supporting inspected development the platform GMP facility INTEGRATED

5. Slide 5: Nualtis is Uniquely Positioned for Growth: Market + Science + Momentum

   Nualtis is Uniquely Positioned for Growth: Market + Science + Momentum SCIENTIFIC FOUNDATION Purpose-driven team boasts MARKET 30+ patents and patent A large niche market applications thanks to 20+ poised to expand: Oral years of R&D experience in Thin Films are a US$3.8B1 differentiated OTF product

6. Slide 6: A Diversified Pipeline Across Therapeutic Areas, Stages of Development and Partner Types

   A Diversified Pipeline Across Therapeutic Areas, Stages of Development and Partner Types Key Molecules Indication Partner Formulation Development Clinical Filing Launch Rizatriptan Migraine Gensco Pharma Buprenorphine1 Chronic Pain Xiromed Undisclosed Undisclosed Undisclosed Human Health Buprenorphi

7. Slide 7: Opportunity Highlights | Company Overview | Product Portfolio | Financials | Corporate Information

   Opportunity Highlights | Company Overview | Product Portfolio | Financials | Corporate Information | Appendix 7

8. Slide 8: Oral Thin Films: A High-Growth Drug Delivery Platform

   Oral Thin Films: A High-Growth Drug Delivery Platform Key Growth Drivers Key OTF Products Global Market Size (US$B) CAGR: 9.3%  Rise in Investment in R&D of Fast-Dissolving Oral Films: Fast- dissolving oral films improve API effectiveness by dissolving in the oral cavity within minutes after contac

9. Slide 9: Oral Thin Films as an Alternative Administration Method With Substantial Differentiation

   Oral Thin Films as an Alternative Administration Method With Substantial Differentiation Nualtis Areas of Differentiation Product Examples Delivery directly through the mucosal lining enables faster onset of action, Bioavailability Tadalafil lower doses and fewer side effects than conventional table

10. Slide 10: Nualtis OTF Technology: Buccal OTF Delivery Can Replicate an I.V. Infusion

    Opportunity Highlights | Company Overview | Product Portfolio | Financials | Corporate Information | Appendix Nualtis OTF Technology: Buccal OTF Delivery Can Replicate an I.V. Infusion Pharmacokinetics / Pharmacodynamics (PK / PD) DMT Plasma Concentration Test Results  Buccal film comparable to IV

11. Slide 11: Nualtis OTF Technology: Buccal OTF Delivery Can Improve on Tablet Results

    Opportunity Highlights | Company Overview | Product Portfolio | Financials | Corporate Information | Appendix Nualtis OTF Technology: Buccal OTF Delivery Can Improve on Tablet Results PK Results Blood Plasma Concentration Results vs. Tablet • Buccal formulation successfully tested against a tablet T

12. Slide 12: Strategically Located in the Growing Life Sciences Hub of Montréal, Quebec

    Opportunity Highlights | Company Overview | Product Portfolio | Financials | Corporate Information | Appendix Strategically Located in the Growing Life Sciences Hub of Montréal, Quebec Facility Location Benefits to Location Proximity to Partners (U.S. Eastern Seaboard) Strong Regional Presence of Su

13. Slide 13: Facility Overview

    Opportunity Highlights | Company Overview | Product Portfolio | Financials | Corporate Information | Appendix Facility Overview  Montreal-based facility with full GMP compliance and continuous three-lane packaging HQ: Montreal line to enable high volume production Canadian Headquarters  Nualtis cu

14. Slide 14: Proven Management Team with Deep Industry Expertise

    Opportunity Highlights | Company Overview | Product Portfolio | Financials | Corporate Information | Appendix Proven Management Team with Deep Industry Expertise Dr. Michael Raven Nadine Paiement CEO CSO With leadership experience from Bayer Oversees oral film formulation and Pharmaceuticals, Atai L

COSCIENS Biopharma — Investor Presentation (September 2026) on 6ix